Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Core One Labs Inc. Stock

Price
Target price
€0.43

€0.43

-1.660%
-0.007
-1.660%
?
 
20.05.22 / Tradegate WKN: A3CSSU / Name: Core One Labs Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Core One Labs Inc. in the next few years
Wizard

Financial data and news for Core One Labs Inc.

sharewise wants to provide you with the best news and tools for Core One Labs Inc., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Core One Labs’ Akome Receives Positive Results from Bioassay Studies

 

Will Look to Advance its Psychedelic Based Formulations

 

Vancouver, British Columbia, Canada - April 2, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU)

irwpresse_en 
0 02.04.22
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
irwpresse_en 
0 20.03.22
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities

 

Vancouver, British Columbia, Canada - March 15, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that

irwpresse_en 
0 15.03.22
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin

 

Successful Breakthrough of Biosynthetic Psilocybin Production Method Progressing Quickly

 

Vancouver, British Columbia, Canada - March 12, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLAB

irwpresse_en 
0 13.03.22
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations

 

Vancouver, British Columbia, Canada - March 4, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that i

irwpresse_en 
0 04.03.22
Core One Labs’ Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)

 

VANCOUVER, British Columbia, March 3, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that its

irwpresse_en 
0 03.03.22
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)

Vancouver, British Columbia, Canada – February 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce

irwpresse_en 
0 21.02.22
Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents

Vancouver, British Columbia, Canada – February 11, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), a life sciences

irwpresse_en 
0 11.02.22
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Vancouver, British Columbia, Canada – February 10, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that

irwpresse_en 
0 10.02.22
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care

Vancouver, British Columbia, Canada – February XX, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that

irwpresse_en 
0 09.02.22
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences

Vancouver, British Columbia, Canada – January 26, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that

irwpresse_en 
0 26.01.22
Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin

 

Vancouver, British Columbia, Canada - January 21, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce tha

irwpresse_en 
0 21.01.22
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022

 

Vancouver, British Columbia, Canada - January 18, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) announces that the special

irwpresse_en 
0 18.01.22
Core One Labs to Host Special Investor Webcast on Tuesday, January 18, 2022

 

Vancouver, British Columbia, Canada - January 15, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce, as

irwpresse_en 
0 16.01.22
Core One Labs Now Also Working to Biosynthesize DMT and Receives License

 

Vancouver, British Columbia, Canada - January 08, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce tha

irwpresse_en 
0 09.01.22